-
1
-
-
80455176700
-
A decade of advances in treatment for advanced non-small cell lung cancer
-
Gettinger S, Lynch T. A decade of advances in treatment for advanced non-small cell lung cancer. Clin Chest Med. 2011;32:839-851.
-
(2011)
Clin Chest Med.
, vol.32
, pp. 839-851
-
-
Gettinger, S.1
Lynch, T.2
-
2
-
-
0026653868
-
Interleukin-2 andinterferon-alpha in the treatment of patients withadvanced non-small-cell lung cancer
-
Jansen R, Slingerland R, Goey S, et al. Interleukin-2 andinterferon-alpha in the treatment of patients withadvanced non-small-cell lung cancer. J Immunother. 1992;12:70-73.
-
(1992)
J Immunother.
, vol.12
, pp. 70-73
-
-
Jansen, R.1
Slingerland, R.2
Goey, S.3
-
3
-
-
0028926389
-
Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer
-
Schiller J, Morgan-Ihrig C, Levitt M. Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer. Am J Clin Oncol. 1995;18:47-51.
-
(1995)
Am J Clin Oncol.
, vol.18
, pp. 47-51
-
-
Schiller, J.1
Morgan-Ihrig, C.2
Levitt, M.3
-
4
-
-
84862903106
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
-
Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-2465.
-
(2012)
N Engl J Med.
, vol.366
, pp. 2455-2465
-
-
Brahmer, J.R.1
Tykodi, S.S.2
Chow, L.Q.3
-
5
-
-
84969395983
-
Atezolizumab monotherapy vs docetaxel in 2L/3L nonsmall cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR)
-
Sep 25-29. Abstract 14LBA
-
Vansteenkiste J, Fehrenbacher L, Spira AI, et al. Atezolizumab monotherapy vs docetaxel in 2L/3L nonsmall cell lung cancer: primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). European Cancer Congress 2015; Sep 25-29. Abstract 14LBA.
-
(2015)
European Cancer Congress
-
-
Vansteenkiste, J.1
Fehrenbacher, L.2
Spira, A.I.3
-
6
-
-
84924809260
-
Evidence and clinical potential
-
Nivolumab in NSCLC
-
Sundar R, Cho B-C, Brahmer JR, et al. Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7(2):85-96.
-
(2015)
Ther Adv Med Oncol
, vol.7
, Issue.2
, pp. 85-96
-
-
Sundar, R.1
Cho, B.-C.2
Brahmer, J.R.3
-
7
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
-
(2012)
N Engl J Med.
, vol.366
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
-
8
-
-
42649125225
-
PD-1 and its ligands in tolerance and immunity
-
Keir M, Butte M, Freeman G, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704.
-
(2008)
Annu Rev Immunol.
, vol.26
, pp. 677-704
-
-
Keir, M.1
Butte, M.2
Freeman, G.3
-
9
-
-
77957664158
-
Programmed death-1 upregulation is correlated with dysfunction of tumorinfiltrating CD8+ T lymphocytes in human non-small cell lung cancer
-
Zhang Y, Huang S, Gong D, et al. Programmed death-1 upregulation is correlated with dysfunction of tumorinfiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol. 2010;7:389-395.
-
(2010)
Cell Mol Immunol.
, vol.7
, pp. 389-395
-
-
Zhang, Y.1
Huang, S.2
Gong, D.3
-
10
-
-
80052476869
-
High expression of PD-L1 in lung cancermay contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
-
Mu C, Huang J, Chen Y, et al. High expression of PD-L1 in lung cancermay contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011;28:682-688.
-
(2011)
Med Oncol.
, vol.28
, pp. 682-688
-
-
Mu, C.1
Huang, J.2
Chen, Y.3
-
11
-
-
33644659256
-
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
-
Peggs KS, Quezada SA, Korman AJ, et al. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006;18:206-213.
-
(2006)
Curr Opin Immunol.
, vol.18
, pp. 206-213
-
-
Peggs, K.S.1
Quezada, S.A.2
Korman, A.J.3
-
12
-
-
84936791837
-
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
-
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-135.
-
(2015)
N Engl J Med.
, vol.373
, pp. 123-135
-
-
Brahmer, J.1
Reckamp, K.L.2
Baas, P.3
-
13
-
-
84948574184
-
-
Common Terminology Criteria for Adverse Events (CTCAE),[cited 2015 Nov 13]
-
Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0 [Internet]. [cited 2015 Nov 13]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf.
-
Version 4.0 [Internet]
-
-
-
14
-
-
84924901863
-
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial
-
Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257-265.
-
(2015)
Lancet Oncol.
, vol.16
, pp. 257-265
-
-
Rizvi, N.A.1
Mazieres, J.2
Planchard, D.3
-
15
-
-
84936791837
-
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
-
Borghaei H, Paz Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(2):123-135.
-
(2015)
N Engl J Med.
, vol.373
, Issue.2
, pp. 123-135
-
-
Borghaei, H.1
Paz Ares, L.2
Horn, L.3
-
16
-
-
84929481480
-
Pembrolizumab for the treatment of non-small-cell lung cancer
-
Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.
-
(2015)
N Engl J Med.
, vol.372
, pp. 2018-2028
-
-
Garon, E.B.1
Rizvi, N.A.2
Hui, R.3
-
17
-
-
84944734156
-
Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)
-
Abstract 8032
-
Rizvi NA, Brahmer JR, Ou SI, et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). 2015 ASCO Annual Meeting. Abstract 8032.
-
2015 ASCO Annual Meeting
-
-
Rizvi, N.A.1
Brahmer, J.R.2
Ou, S.I.3
-
18
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
-
(2010)
N Engl J Med.
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
-
19
-
-
84863911486
-
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase II study
-
Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30:2046-2054.
-
(2012)
J Clin Oncol.
, vol.30
, pp. 2046-2054
-
-
Lynch, T.J.1
Bondarenko, I.2
Luft, A.3
-
20
-
-
84959564276
-
Safety and efficacy of first-line nivolumab (Anti-programmed death-1 [PD-1]) and ipilimumab in non-small cell lung cancer (NSCLC)
-
Sep 7. Abstract ORAL02.05
-
Rizvi N, Gettinger SN, Goldman J, et al. Safety and efficacy of first-line nivolumab (Anti-programmed death-1 [PD-1]) and ipilimumab in non-small cell lung cancer (NSCLC). 16th World conference on lung cancer. 2015 Sep 7. Abstract ORAL02.05.
-
(2015)
16th World Conference on Lung Cancer
-
-
Rizvi, N.1
Gettinger, S.N.2
Goldman, J.3
-
21
-
-
84939518267
-
Phase I/II study (CheckMate 032) of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC)
-
Abstract 7503
-
Antonia SJ, Bendell J, Taylor M, et al. Phase I/II study (CheckMate 032) of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC). 2015 ASCO Annual Meeting. 2015. Abstract 7503.
-
(2015)
2015 ASCO Annual Meeting
-
-
Antonia, S.J.1
Bendell, J.2
Taylor, M.3
-
22
-
-
84942138310
-
Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced nonsmall cell lung cancer (NSCLC): KEYNOTE-021 cohort D
-
Abstract 8011
-
Patnaik AM, Socinski MA, Gubens MA, et al. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced nonsmall cell lung cancer (NSCLC): KEYNOTE-021 cohort D. 2015 American society of clinical oncology annual meeting. 2015. Abstract 8011.
-
(2015)
2015 American Society of Clinical Oncology Annual Meeting
-
-
Patnaik, A.M.1
Socinski, M.A.2
Gubens, M.A.3
-
23
-
-
0027181697
-
Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies
-
Vialettes B, Guillerand MA, Viens P, et al. Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies. Acta Endocrinol (Copenh). 1993;129:31-38.
-
(1993)
Acta Endocrinol (Copenh)
, vol.129
, pp. 31-38
-
-
Vialettes, B.1
Guillerand, M.A.2
Viens, P.3
-
24
-
-
78751559991
-
Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
-
Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol. 2011;164:303-307.
-
(2011)
Eur J Endocrinol
, vol.164
, pp. 303-307
-
-
Min, L.1
Vaidya, A.2
Becker, C.3
-
26
-
-
84918583260
-
Guidelines for the treatment of hypothyroidism: Prepared by the American thyroid association task force on thyroid hormone replacement
-
Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American thyroid association task force on thyroid hormone replacement. Thyroid. 2014;24:1670-1751.
-
(2014)
Thyroid
, vol.24
, pp. 1670-1751
-
-
Jonklaas, J.1
Bianco, A.C.2
Bauer, A.J.3
-
27
-
-
84899873585
-
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: A comprehensive retrospective review from a single institution
-
Ryder M, Callahan M, Postow MA, et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21:371-381.
-
(2014)
Endocr Relat Cancer
, vol.21
, pp. 371-381
-
-
Ryder, M.1
Callahan, M.2
Postow, M.A.3
-
29
-
-
84888226962
-
Endocrine sideeffects of anti-cancer drugs: MAbs and pituitary dysfunction: Clinical evidence and pathogenic hypotheses
-
Torino F, Barnabei A, Paragliola RM, et al. Endocrine sideeffects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol. 2013;169:R153-64.
-
(2013)
Eur J Endocrinol.
, vol.169
, pp. R153-R164
-
-
Torino, F.1
Barnabei, A.2
Paragliola, R.M.3
-
31
-
-
84864067813
-
Hyponatremia associated with ipilimumab-induced hypophysitis
-
Barnard ZR, Walcott BP, Kahle KT, et al. Hyponatremia associated with ipilimumab-induced hypophysitis. Med Oncol. 2012;29:374-377.
-
(2012)
Med Oncol.
, vol.29
, pp. 374-377
-
-
Barnard, Z.R.1
Walcott, B.P.2
Kahle, K.T.3
-
32
-
-
77949274549
-
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: Serious immune related adverse events across a spectrum of cancer subtypes
-
Dillard T, Yedinak CG, Alumkal J, et al. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary. 2010;13:29-38.
-
(2010)
Pituitary
, vol.13
, pp. 29-38
-
-
Dillard, T.1
Yedinak, C.G.2
Alumkal, J.3
-
33
-
-
84864052441
-
Management of immune-related adverse events and kinetics of response with ipilimumab
-
Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691-2697.
-
(2012)
J Clin Oncol.
, vol.30
, pp. 2691-2697
-
-
Weber, J.S.1
Kähler, K.C.2
Hauschild, A.3
-
34
-
-
84946221495
-
Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-smallcell lung cancer
-
[Epub ahead of print]
-
Chow LQM. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-smallcell lung cancer. Am Soc Clin Oncol Educ Book. 2013. doi:10.1200/EdBook-AM.2013.33.e280. [Epub ahead of print]
-
(2013)
Am Soc Clin Oncol Educ Book
-
-
Chow, L.Q.M.1
-
35
-
-
84938309673
-
Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC
-
May
-
Antonia SJ, Goldberg SB, Balmanoukian AS, et al. Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. J Clin Oncol (Meeting Abstracts). 2015 May;33 (15):suppl 3014.
-
(2015)
J Clin Oncol (Meeting Abstracts)
, vol.33
, Issue.15
-
-
Antonia, S.J.1
Goldberg, S.B.2
Balmanoukian, A.S.3
-
36
-
-
84944802880
-
Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer
-
May
-
Oxnard GR, Ramalingam SS, Ahn M, et al. Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer. J Clin Oncol (Meeting Abstracts). 2015 May;33(15):suppl 2509.
-
(2015)
J Clin Oncol (Meeting Abstracts)
, vol.33
, Issue.15
-
-
Oxnard, G.R.1
Ramalingam, S.S.2
Ahn, M.3
-
37
-
-
84944728607
-
Safety and tolerability results from a phase i study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PDL1) antibody, combined with gefitinib in patients (pts) with nonsmall-cell lung cancer (NSCLC)
-
May
-
Creelan BC, Chow LQ, Kim D, et al. Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PDL1) antibody, combined with gefitinib in patients (pts) with nonsmall-cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts). 2015 May;33(15):suppl 3047.
-
(2015)
J Clin Oncol (Meeting Abstracts)
, vol.33
, Issue.15
-
-
Creelan, B.C.1
Chow, L.Q.2
Kim, D.3
-
38
-
-
36748999428
-
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade
-
Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13:6681-6688.
-
(2007)
Clin Cancer Res.
, vol.13
, pp. 6681-6688
-
-
Downey, S.G.1
Klapper, J.A.2
Smith, F.O.3
-
40
-
-
24944459890
-
-
J Clin Oncol. 2005;23:6043-6053.
-
(2005)
J Clin Oncol
, vol.23
, pp. 6043-6053
-
-
|